TY - JOUR
T1 - A dietary restriction influences the progression but not the initiation of MSG-induced nonalcoholic steatohepatitis
AU - Fujimoto, Makoto
AU - Tsuneyama, Koichi
AU - Nakanishi, Yuko
AU - Salunga, Thucydides L.
AU - Nomoto, Kazuhiro
AU - Sasaki, Yoshiyuki
AU - Iizuka, Seiichi
AU - Nagata, Mitsunobu
AU - Suzuki, Wataru
AU - Shimada, Tsutomu
AU - Aburada, Masaki
AU - Shimada, Yutaka
AU - Gershwin, M. Eric
AU - Selmi, Carlo
PY - 2014/3/1
Y1 - 2014/3/1
N2 - The metabolic syndrome is a major worldwide health care issue and a dominant risk factor for cardiovascular disease. The liver manifestations of this syndrome include nonalcoholic fatty liver disease (NAFLD) and its progressive variant nonalcoholic steatohepatitis (NASH). Although significant research has been performed, the basic pathogenesis of NAFLD/NASH remains controversial and effective treatments are still unavailable. We have previously reported on a murine model of NASH induced by the neonatal injection of monosodium glutamate (MSG), which includes the clinical manifestations of central obesity, diabetes, hyperlipidemia, and ultimately liver inflammation, fibrosis, and cancer. Although MSG is considered a safe food additive, its administration to pregnant rats increases the voracity and growth hormone levels in the offspring. To further understand the biology of this model, we have investigated the influence of the calorie intake on these clinical manifestations by feeding animals a restrictive diet. MSG-treated animals fed a restrictive diet continue to manifest obesity and early stage NASH but have improvements in serum lipid profiles. At 12 months of age, mice had manifestations of obesity, whether animals were fed a restricted or control diet, but animals fed a restrictive diet had a reduction in the progression of NASH. In conclusion, MSG appears to be a critical factor in the initiation of obesity, whereas calorie intake may modulate the progression of disease.
AB - The metabolic syndrome is a major worldwide health care issue and a dominant risk factor for cardiovascular disease. The liver manifestations of this syndrome include nonalcoholic fatty liver disease (NAFLD) and its progressive variant nonalcoholic steatohepatitis (NASH). Although significant research has been performed, the basic pathogenesis of NAFLD/NASH remains controversial and effective treatments are still unavailable. We have previously reported on a murine model of NASH induced by the neonatal injection of monosodium glutamate (MSG), which includes the clinical manifestations of central obesity, diabetes, hyperlipidemia, and ultimately liver inflammation, fibrosis, and cancer. Although MSG is considered a safe food additive, its administration to pregnant rats increases the voracity and growth hormone levels in the offspring. To further understand the biology of this model, we have investigated the influence of the calorie intake on these clinical manifestations by feeding animals a restrictive diet. MSG-treated animals fed a restrictive diet continue to manifest obesity and early stage NASH but have improvements in serum lipid profiles. At 12 months of age, mice had manifestations of obesity, whether animals were fed a restricted or control diet, but animals fed a restrictive diet had a reduction in the progression of NASH. In conclusion, MSG appears to be a critical factor in the initiation of obesity, whereas calorie intake may modulate the progression of disease.
KW - diabetes
KW - functional foods
KW - hepatocellular carcinoma
KW - metabolic syndrome
KW - nonalcoholic fatty liver disease
UR - http://www.scopus.com/inward/record.url?scp=84896902437&partnerID=8YFLogxK
U2 - 10.1089/jmf.2012.0029
DO - 10.1089/jmf.2012.0029
M3 - 学術論文
C2 - 24588719
AN - SCOPUS:84896902437
SN - 1096-620X
VL - 17
SP - 374
EP - 383
JO - Journal of medicinal food
JF - Journal of medicinal food
IS - 3
ER -